Sage Therapeutics scraps Alzheimer’s drug development
Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide
Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a late-stage trial, sending its shares down 10% in premarket trading.
SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas ...
Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...
Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...
TD Cowen analyst Ritu Baral maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of ...
Last month, TikTok user Hana Katana accused the rapper of sexual assaulting her at Chris Brown's home when she was 18.
Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...
Rapper Sage the Gemini, best known for his hits “Red Nose” and “Gas Pedal,” is facing serious allegations of sexual assault stemming from an incident that allegedly took place at Chris Brown’s Los ...
Twice a year Purple Sage Pottery opens its doors for an open studio sale. Sixteen local potters will offer a variety of ...
A woman has claimed that “Gas Pedal” rapper Sage the Gemini sexually assaulted her inside Chris Brown’s home in Los Angeles.
Bank of America Securities analyst Tazeen Ahmad has reiterated their bearish stance on SAGE stock, giving a Sell rating on October 4. Tazeen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback